Aeterna nach dem Split
Heron, warum schreibst Du das??
Selbst Doddy sagte bloß:
**We are confident in our ability to complete the trial and report top-line results in early 2017. We are also on track to file an NDA for Macrilen during the first half of 2017 if the results of the trial support.**
.. und sogar dies ist die übliche Null und Gummi-Aussage .. ..
schon was kommen ;-)...
wie in den anderen Threads geschrieben, aber hier nochmal..
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
https://clinicaltrials.gov/ct2/show/NCT02238496?term=aezs&rank=11
Drug catalyst information is displayed when you hover over the stage bar graph.
http://biopharmcatalyst.com/company/aezs
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
03/31/2017
Phase 3 data due early 2017 with NDA filing due 1H 2017 pending positive data.
Zoptrex
Endometrial cancer
03/31/2017
Phase 3 data due 1Q 2017.
http://www.smarteranalyst.com/2016/08/01/...e-agreement-deal-zoptrex/
https://www.barchart.com/stocks/quotes/AEZS/opinion
2nd Resistance Point 3.98
1st Resistance Point 3.92
Last Price 3.85
1st Support Level 3.77
2nd Support Level 3.68
wenn Zoptrex Ende 2017 zündet, wird das ein größeres Feuerwerk, als 2000 in Berlin zur Jahrtausendwende.
Heißt aber nicht, dass es nicht schon nach positiven Top Line Daten im Februar für 15-20$ im Kurs sorgen kann.
Das Risiko bleibt.Ist aber nur Geld das man verliert, wenns schief geht.Nicht tragisch.
https://www.canadianinsider.com/company?menu_tickersearch=AEZ%20
As of 11:59pm ET December 13th, 2016
Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction Volume or Value Price
Dec 13/16 Dec 13/16 Limoges, Gérard A. Indirect Ownership Common Shares 10 - Acquisition in the public market 1,200 $4.99
Dec 8/16 Dec 6/16 Teifel, Michael Direct Ownership Options 50 - Grant of options 20,000
Dec 8/16 Dec 6/16 Sachse, Richard Direct Ownership Options 50 - Grant of options 57,630
Dec 8/16 Dec 6/16 Günther, Eckhard Direct Ownership Options 50 - Grant of options 10,000
Dec 8/16 Dec 6/16 Dinges, Jude Direct Ownership Options 50 - Grant of options 86,580
Dec 8/16 Dec 6/16 Newport, Ken Direct Ownership Options 50 - Grant of options 7,850
Dec 8/16 Dec 6/16 Limoges, Gérard A. Direct Ownership Options 50 - Grant of options 7,850
Dec 8/16 Dec 6/16 Ernst, Jürgen Direct Ownership Options 50 - Grant of options 7,850
Dec 8/16 Dec 6/16 Egbert, Carolyn Direct Ownership Options 50 - Grant of options 7,850
Dec 8/16 Dec 6/16 Cardiff, Michael Direct Ownership Options 50 - Grant of options 7,850
Dec 13/16 Dec 13/16 Limoges, Gérard A. Indirect Ownership Common Shares 10 - Acquisition in the public market 1,200 $4.99
http://ir.aezsinc.com/stock-information?qm_page=63892
12:46 EST 14.12.2016
Outstanding: 11,97m
Float: 9,89m
https://www.tipranks.com/stocks/aezs
Based on 3 ranked analysts offering 12 month price targets for AEZS in the last 3 months, the average price target is $9.83, with a high estimate of $12.00 and a low estimate of $7.50.
Avg. Price Target
$9.83
(160.05% Upside)
Queelle
http://www.postandcourier.com/business/...11e6-a037-bfa357e85be9.html
The company says that to raise the new funding, it sold stock and the rights to buy more shares later to a "single healthcare dedicated institutional investor" in the U.S., which it didn't name. Theodore declined to name the hedge fund, but said the firm now owns about a fifth of Aeterna Zentaris's stock.